Harly Greenberg, MD
Pulmonary Disease · New Hyde Park, NYNPI 1730249871
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), education and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 45.9% of the total. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 4 payments — averaging $81.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$150
- Harmony Biosciences LLC$140
- ZOLL Medical Corporation$37
Across 77 payments — averaging $3886.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Harmony Biosciences LLC$204K
- Inspire Medical Systems, Inc.$63K
- Vanda Pharmaceuticals Inc.$17K
- ZOLL Respicardia, Inc.$12K
- Boehringer Ingelheim$3K
- Novartis$2K
What the payments were for
- Consulting fees$15046%
- Food & beverage$3711%
- Education$14043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Harmony Biosciences LLC | 2 | $140 |
| ZOLL Medical Corporation | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$327 in reported general payments places this provider in the 35th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NeuproRotigotine | 11 | $22,725 |
| BelsomraSuvorexant | 51 | $22,050 |
| QuviviqDaridorexant Hcl | 17 | $8,296 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,605 |
| Armodafinil | 42 | $1,316 |
| Mirtazapine | 28 | $746 |
| Modafinil | 21 | $720 |
| Eszopiclone | 14 | $471 |
| Zolpidem Tartrate | 43 | $438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $404 |
| Pregabalin | 33 | $385 |
| Clonazepam | 29 | $272 |
| Fluticasone Propionate | 26 | $262 |
| Trazodone Hcl | 12 | $229 |
| Gabapentin | 12 | $81 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Hyde Park
- Abhinav AgrawalNew Hyde Park$55K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.